mRNA-3927

Phase 2Recruiting

0 views this week 0 watching

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Propionic Acidemia

Conditions

Propionic Acidemia

Trial Timeline

Nov 9, 2021 → Dec 4, 2029

NCT ID

NCT05130437

About mRNA-3927

mRNA-3927 is a phase 2 stage product being developed by Moderna for Propionic Acidemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05130437. Target conditions include Propionic Acidemia.

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05130437	Phase 2	Recruiting	Nov 9, 2021	Dec 4, 2029	Propionic Acidemia
NCT04159103	Phase 2	Recruiting	Apr 15, 2021	Aug 31, 2027	Propionic Acidemia

Competing Products

3 competing products in Propionic Acidemia

See all competitors

Product	Company	Stage
"The MaP Study": Mapping the Patient Journey in MMA and PA	Moderna	Preclinical
A Retrospective Study to Characterize Participants With Propionic Acidemia	Moderna	Preclinical
mRNA-3927	Moderna	Phase 2